Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,986 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Orlando, FloridaAges 18 years+ - NCT07230691Recruiting
Study of amivantamab for advanced EGFR-mutated lung cancer
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
GrazAges 18 years+ - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT06096844RecruitingPhase 3
Chemo plus immunotherapy vs immunotherapy alone for older adults with advanced lung cancer
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
Fayetteville, ArkansasAges 70 years+ - NCT07030712RecruitingPhase 1
Study of MK-8294 for advanced solid tumors
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Chicago, IllinoisAges 18 years+ - NCT07680556Recruiting
Exercise to boost immunotherapy for advanced kidney cancer
This trial tests whether adding a structured exercise program to standard immunotherapy can help the treatment work better for people with advanced renal cell carcinoma.
Arnhem, GelderlandAges 18 years+ - NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT07787208RecruitingPhase 1
Experimental drug for advanced solid tumors
This trial tests an investigational drug called ONO-7429 for people with advanced or recurrent solid tumors that have not responded to standard treatments. The goal is to see if the drug can help control the cancer.
Kashiwa, ChibaAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Fountain Valley, CaliforniaAges 18 years+ - NCT07227831Recruiting
TheraBionic device for advanced hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Bay City, MichiganAges 22 years+ - NCT07789210RecruitingPhase 2
Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06523556RecruitingPhase 1/Phase 2
Study of axatilimab with or without azacitidine for advanced blood cancers
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
Columbus, OhioAges 18 years+ - NCT07755540RecruitingPhase 2
Group music therapy for chronic pain in active duty service members
This study tests whether participating in group music therapy sessions can help active duty service members manage chronic pain. It aims to see if music therapy can improve pain symptoms and quality of life.
Anchorage, AlaskaAges 18–64 - NCT07652359Recruiting
Community care research for Monterey residents
This study looks at how to better support people getting primary care in the Monterey area, especially those from diverse or lower-income backgrounds. It aims to make care more equal and helpful.
Palo Alto, CaliforniaAges 18 years+ - NCT07789093Recruiting
Coaching support for advanced cancer patients and caregivers
This trial tests a coaching program to help patients with advanced cancer and their caregivers prepare for and recover from palliative surgery or procedures that aim to relieve symptoms and improve quality of life. It explores whether this coaching improves communication and well-being.
SingaporeAges 21–99 - NCT07474727RecruitingPhase 2
Study of AMT-676 combination therapy for advanced colorectal cancer
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Fuzhou, FujianAges 18–80 - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT07403721RecruitingPhase 1
Study of AMG 436 for MSI-H/dMMR Cancers
This study tests an experimental drug called AMG 436, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change (MSI-H or dMMR). The goal is to see if the drug can shrink tumors and if it is safe.
Irvine, CaliforniaAges 18–99 - NCT07544589RecruitingPhase 1
Testing DISP-10 for Advanced Gastrointestinal Cancers
This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.
Duarte, CaliforniaAges 18 years+ - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT06916507Recruiting
Early Use of a Parkinson's Pump in Advanced Stages
This study tests a new pump-delivered combination of Parkinson's medications (foslevodopa/foscarbidopa) in adults who have recently started having motor fluctuations but are not yet using other device therapies. It aims to see how well it works in real life and may offer better symptom control.
Allensbach, Baden-WurttembergAges 18–64 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,986 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.